|
Molecular properties generated using the CDK |
Classification ![]() |
|
Compound class | Synthetic organic |
IUPAC Name ![]() |
1-[5-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-2, 3-dihydroindol-1-yl]-2-[3-fluoro-5-(trifluoromethyl)phenyl]ethanone |
Synonyms ![]() |
|
3-fluoro-GSK2606414 | compound 38 [PMID: 22827572] [1] | GSK PERK Inhibitor |
Database Links ![]() |
|
CAS Registry No. | 1337531-89-1 (source: SciFinder) |
ChEMBL Ligand | CHEMBL2171125 |
GtoPdb PubChem SID | 178103351 |
PubChem CID | 66561167 |
Search Google for chemical match using the InChIKey | PXVQGBJMIQCDEX-UHFFFAOYSA-N |
Search Google for chemicals with the same backbone | PXVQGBJMIQCDEX |
Search UniChem for chemical match using the InChIKey | PXVQGBJMIQCDEX-UHFFFAOYSA-N |
Search UniChem for chemicals with the same backbone | PXVQGBJMIQCDEX |
Comments |
GSK2606414 is an analogue identified by a medicinal chemistry study to find novel, potent and selective protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) inhibitors [1]. The official HGNC endorsed name for PERK is eukaryotic translation initiation factor 2-alpha kinase 3 (with gene symbol EIF2AK3). GSK2606414 is highly selective and is orally available. |